Addition of a tissue-factor/factor VIIa inhibitor to standard treatments in NSTE-ACS managed with an early invasive strategy: Results of the phase 2 ANTHEM-TIMI 32 double-blind randomized clinical trial

Author Department

Medicine

Document Type

Presentations, Research

Publication Date

11-1-2005

Share

COinS